bristol myers squibb announced early thursday that a closely watched phase 2 trial of the company’s experimental drug deucravacitinib as a treatment for ulcerative colitis had missed its predetermined efficacy targets the trial did not hit its primary endpoint of clinical remission after 12 weeks the company said and also failed to hit secondary efficacy endpoints the trial did not raise any new safety concerns